Apeloa PharmaceuticalLtd Dirección

Dirección controles de criterios 4/4

El CEO de Apeloa PharmaceuticalLtd es Chun He, nombrado en Jan 2024, tiene una permanencia de menos de un año. posee directamente un 0.004% de las acciones de la empresa, con un valor de CN¥750.11K. La antigüedad media del equipo directivo y de la junta directiva es de 11.8 años y 5.8 años, respectivamente.

Información clave

Chun He

Chief Executive Officer (CEO)

CN¥903.6k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.004%
Permanencia media de la dirección	11.8yrs
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Chun He (50 yo)

less than a year

Permanencia

CN¥903,600

Compensación

Mr. Chun He is General Manager of Apeloa Pharmaceutical Co. Ltd. since 2024 and served as its Senior Deputy General Manager until 2024 and served as its GM of Formulation Division since June 2022 until 202...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Fangmeng Zhu	Chairman	11.8yrs	CN¥2.40m	0.019% CN¥ 3.8m
Chun He	General Manager	less than a year	CN¥903.60k	0.0038% CN¥ 750.1k
Xinliang Xu	Vice Chairman	less than a year	CN¥1.44m	0.0095% CN¥ 1.9m
Jinhui Zhang	Chief Financial Officer	5.8yrs	CN¥653.60k	0.00038% CN¥ 75.4k
Min Jin	Senior Deputy GM & GM of API Division	no data	CN¥903.60k	0.0043% CN¥ 857.3k
Lei Cai	Deputy GM & GM of CDMO Division	no data	CN¥810.00k	0.0043% CN¥ 857.3k
Yuwang Zhou	Deputy GM & Secretary	no data	CN¥633.60k	sin datos
Hui Zhang	Chief Technology Officer	13.5yrs	CN¥360.00k	sin datos

11.8yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 000739 es experimentado (11.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Fangmeng Zhu	Chairman	11.8yrs	CN¥2.40m	0.019% CN¥ 3.8m
Xinliang Xu	Vice Chairman	less than a year	CN¥1.44m	0.0095% CN¥ 1.9m
Xing Wu	Non-Independent Director	11.8yrs	CN¥2.80m	0.0086% CN¥ 1.7m
Wencai Xu	Non-Independent Director	22.9yrs	sin datos	sin datos
Tiangao Hu	Non-Independent Director	16.5yrs	sin datos	sin datos
Xiangquan Ge	Supervisor	1.6yrs	sin datos	sin datos
Guoping Li	Chairman of the Supervisory Board	6.9yrs	sin datos	sin datos
Ling Chen	Independent Director	4.6yrs	CN¥88.20k	sin datos
Juan Ping Qian	Independent Director	3.6yrs	CN¥88.20k	sin datos
Weiguang Pan	Independent Director	2.7yrs	CN¥45.00k	sin datos

5.8yrs

Permanencia media

54.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 000739 se considera experimentada (5.8 años de antigüedad promedio).

Apeloa PharmaceuticalLtd Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024

Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.21 in 3Q 2023)

Investor sentiment improves as stock rises 22%

Apeloa Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.31 in 2Q 2023)

Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 16, 2024

Dividend increased to CN¥0.32

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1Q 2023)

Apeloa Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 19, 2024

Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024

Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024

Full year 2023 earnings released: EPS: CN¥0.90 (vs CN¥0.84 in FY 2022)

Investor sentiment improves as stock rises 17%

Apeloa Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Mar 08, 2024

Investor sentiment deteriorates as stock falls 16%

Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 3Q 2022)

Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2023 Results on Aug 15, 2023

Apeloa Pharmaceutical Co.,Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 22 May 2023

Full year 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.81 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.18 in 3Q 2021)

Investor sentiment improved over the past week

First half 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.47 in 1H 2021)

Investor sentiment improved over the past week

Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) announces an Equity Buyback for CNY 400 million worth of its shares.

First quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.18 in 1Q 2021)

Apeloa Pharmaceutical Co.,Ltd Proposes Final Dividend on A Shares for the Year 2021, Payable on 18 April 2022

Apeloa Pharmaceutical Co.,Ltd Announces Cash Dividend for 2021

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.23 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.69 (vs CN¥0.47 in FY 2019)

Revenue misses expectations

New 90-day high: CN¥25.52

Apeloa Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 12, 2021

New 90-day high: CN¥24.79

Third quarter earnings released

New 90-day low: CN¥22.50

Apeloa Pharmaceutical Co.,Ltd to Report Q3, 2020 Results on Oct 22, 2020

New 90-day high - CN¥27.14

Earnings released

New 90-day high - CN¥25.93

Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 18, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad